Latest financial model shows substantial net benefits for sponsors that use DCTs.
In their latest financial modeling of Medable’s operational data, Tufts Center for the Study of Drug Development’s (CSDD) provides the first quantitative data showcasing why and how DCTs benefit sponsors.
Read through the findings below, and take some time to learn about our mission, vision, and impact with a letter from our CEO, Michelle Longmire and our first ever “Medable Matters” report.